The field of theranostics is rapidly advancing, driven by the goals of enhancing patient care.
Recent breakthroughs in artificial intelligence (AI) and its innovative theranostic applications …

In the last years, theranostics has expanded the therapeutic options available for prostate
cancer patients. In this review, we explore this dynamic field and its potential to revolutionize …

Prostate cancer is the second leading cause of cancer-related deaths in men in the United
States. Imaging techniques such as CT, MRI, and bone scans have traditionally been used …

Prospective results have demonstrated favorable safety and efficacy of [177Lu] Lu-PSMA
radiopharmaceutical therapy for up to 6 cycles in men with metastatic castration-resistant …

Prostate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed
by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular …

Background and objective: Innovations have improved outcomes in advanced prostate
cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that …

Candidates for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy
(RLT) of metastatic castration-resistant prostate cancer (mCRPC) frequently have …

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in
the majority of prostate cancer (PCa). PSMA has an enzymatic function that makes metabolic …

This review paper highlights the transformative role of PSMA-targeted diagnostics and
therapy in prostate cancer management, particularly focusing on 177 Lu-PSMA-617 …

Background The aim of this study was to provide quantitative evidence for the potential of
PSMA-targeting radioligand therapy (RLT) as treatment approach for malignant brain …